Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 11/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276230 | 1.00 | RIPK1 (0.43) | RIPK1ESR2NR1H2PIK3R1PIK3CA | |
| SCHEMBL3276974 | 0.83 | ABHD6 (0.50) | RIPK1ESR2NR1H2PIK3CAMTOR | |
| SCHEMBL3281590 | 0.80 | ESR2 (0.48) | RIPK1ESR2NR1H2USP2SMN1; SMN2 | |
| SCHEMBL3277235 | 0.80 | ESR2 (0.44) | RIPK1ESR2NR1H2USP2SMN1; SMN2 | |
| SCHEMBL3277231 | 0.80 | ESR2 (0.44) | RIPK1ESR2NR1H2USP2SMN1; SMN2 | |
| SCHEMBL3283648 | 0.79 | ESR2 (0.47) | RIPK1ESR2NR1H2USP2SMN1; SMN2 | |
| SCHEMBL2986459 | 0.78 | ESR2 (0.65) | RIPK1ESR2NR1H2USP2SMN1; SMN2 | |
| SCHEMBL31576025 | 0.77 | ESR2 (0.49) | RIPK1ESR2NR1H2PIK3CAMTOR | |
| SCHEMBL3276386 | 0.77 | ESR2 (0.51) | RIPK1ESR2NR1H2USP2SMN1; SMN2 | |
| SCHEMBL21526480 | 0.77 | NR1H2 (0.66) | RIPK1ESR2NR1H2PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | RIPK1 4189/4885ESR2 1102/4885NR1H2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.